KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Receivables (2020 - 2025)

Historic Change in Receivables for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $3.4 million.

  • AbCellera Biologics' Change in Receivables fell 8268.26% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.8 million, marking a year-over-year decrease of 4309.08%. This contributed to the annual value of $75.1 million for FY2024, which is 6354.04% up from last year.
  • As of Q3 2025, AbCellera Biologics' Change in Receivables stood at $3.4 million, which was down 8268.26% from $11.4 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Change in Receivables peaked at $32.2 million during Q2 2023, and registered a low of -$7.9 million during Q1 2023.
  • In the last 5 years, AbCellera Biologics' Change in Receivables had a median value of $10.4 million in 2023 and averaged $10.4 million.
  • Over the last 5 years, AbCellera Biologics' Change in Receivables had its largest YoY gain of 190000.0% in 2023, and its largest YoY loss of 19044.68% in 2023.
  • Over the past 5 years, AbCellera Biologics' Change in Receivables (Quarter) stood at $3.1 million in 2021, then surged by 522.83% to $19.0 million in 2022, then plummeted by 45.18% to $10.4 million in 2023, then surged by 99.86% to $20.9 million in 2024, then crashed by 83.54% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $11.4 million for Q2 2025, and $1.1 million during Q1 2025.